Physician profile
Keith Lipsitz
NPI 1114915857
$1,837.29
in general payments reported to CMS, 2019-2025
14 companies · $41.20 in 2025
The $41.20 reported for 2025 was less than what a typical Anesthesiology provider received nationally (typical 2025 total: $58.09).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $312 · 2020: $193 · 2021: $380 · 2022: $751 · 2023: $84.79 · 2024: $74.33 · 2025: $41.20.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $200.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $200.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $469.36 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $410.59 | 2019-2025 | Entyvio |
| Abbvie INC. | $370.42 | 2019-2022 | |
| Qol Medical, LLC | $172.24 | 2021-2022 | |
| Celgene Corporation | $67.27 | 2022-2024 | Zeposia |
| Janssen Biotech, INC. | $64.19 | 2020-2025 | Simponi Aria, Tremfya, Simponi |
| Merck Sharp & Dohme LLC | $61.50 | 2020-2023 | Bridion |
| Evoke Pharma, INC. | $50.12 | 2022 | |
| Intercept Pharmaceuticals, INC. | $41.53 | 2019-2022 | |
| Ferring Pharmaceuticals INC. | $34.45 | 2020-2024 | Rebyota |
| Braintree Laboratories, INC. | $33.19 | 2022 | |
| Nestle Healthcare Nutrition INC. | $22.52 | 2021 | |
| Shield Therapeutics INC | $21.84 | 2024 | |
| Daiichi Sankyo INC. | $18.07 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Keith Lipsitz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.